KOD - コディアック・サイエンシズ （Kodiak Sciences Inc） コディアック・サイエンシズKODのチャート
KODの企業情報
| symbol | KOD |
|---|---|
| 会社名 | Kodiak Sciences Inc （コディアック・サイエンシズ） |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate KSI-301 is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501 a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. コディアック・サイエンシズは米国のバイオ医薬品企業。羅漢率の高い眼科疾患のための新たな治療薬の開発に従事。主な製品候補には、加齢黄斑変性症および糖尿病性網膜症のための抗血管内皮増殖因子薬KSI-301があるほか、前臨床段階のプロジェクトとして糖尿病黄斑浮腫やぶどう膜炎の治療薬の臨床試験を手掛ける。本社所在地はカリフォルニア州パロアルト。 Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. |
| 本社所在地 | 2631 Hanover Street Palo Alto CA 94304 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 650-281-0850 |
| 設立年月日 | 39965 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 28人 |
| url | www.kodiak.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kod |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.81400 |
| 終値（lastsale） | 10.01 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 343.04880 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 419.03180 |
| 当期純利益 | 当期純利益（百万ドル） -32.48200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Kodiak Sciences Inc revenues was not reported. Net loss increased 39% to $16.3M. Higher net loss reflects Interest Expense increase from $12K to $3.3M (expense) General and administrative increase of 85% to $3M (expense) Stock-based Compensation in SGA increase from $52K to $384K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.33 to -$0.46. |
KODのテクニカル分析
KODのニュース
Kodiak Sciences files for $350M mixed securities offering 2023/05/15 21:40:32 Seeking Alpha
Kodiak Sciences (KOD) has filed for a $350M mixed shelf securities offering. Read more here.
Kodiak Sciences Inc. Files $350M Mixed Shelf 2023/05/15 21:17:01 Investing.com
https://www.investing.com/news/assorted/kodiak-sciences-inc-files-350m-mixed-shelf-432SI-3083002
Kodiak Sciences GAAP EPS of -$1.35 2023/05/15 20:57:03 Seeking Alpha
Kodiak Sciences press release (KOD): Q1 GAAP EPS of -$1.35.Kodiak ended the first quarter of 2023 with $421.2 million of cash, cash equivalents and marketable securities.
Kodiak Sciences (KOD) Investor Presentation - Slideshow 2023/04/04 17:37:38 Seeking Alpha
The following slide deck was published by Kodiak Sciences Inc.
Kodiak, Arcturus top healthcare gainers; ProQR, Sharecare among losers 2023/03/29 14:05:07 Seeking Alpha
Kodiak Sciences (KOD) +19%. Arcturus Therapeutics (ARCT) +16%. ProQR Therapeutics (PRQR) -31%. Sharecare (SHCR) -29%.
Kodiak Sciences (KOD): A Chance To Change The Narrative 2023/02/08 14:55:43 Seeking Alpha
Kodiak stock was crushed last Feb. when its lead developmental asset failed to meet its primary end point. Check out if KOD stock is now worthy of a small bet.
Thinking Of Investing In Kodiak Sciences Inc. (NASDAQ: KOD) Stock? Read This First 2022/12/31 20:00:00 Stocks Register
Kodiak Sciences Inc. (NASDAQ:KOD) shares, rose in value on Friday, 12/30/22, with the stock price up by 4.22% to the previous day’s close as strong demand from buyers drove the stock to $7.16. Actively observing the price movement in the last trading, the stock closed the session at $6.87, falling within a range of $6.68 … Thinking Of Investing In Kodiak Sciences Inc. (NASDAQ: KOD) Stock? Read This First Read More »
CapitalOne Starts Kodiak Sciences Inc. at Overweight 2022/11/15 13:49:04 Investing.com
https://www.investing.com/news/pro/capitalone-starts-kodiak-sciences-inc-at-overweight-432SI-2944700
Kodiak: Turnaround Strategy Has Shown Life Thus Far (NASDAQ:KOD) 2022/11/14 18:17:47 Seeking Alpha
Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Read the outlook here.
Kodiak Sciences Inc. (KOD) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/11 12:24:00 US Post News
The share price of Kodiak Sciences Inc. (NASDAQ:KOD) rose to $7.12 per share on Thursday from $6.73. While Kodiak Sciences Inc. has overperformed by 5.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KOD fell by -93.63%, with highs and lows ranging from $116.78 to $4.90, […]
CapitalOne Starts Kodiak Sciences Inc. at Overweight 2022/11/15 13:49:04 Investing.com
https://www.investing.com/news/pro/capitalone-starts-kodiak-sciences-inc-at-overweight-432SI-2944700
Kodiak: Turnaround Strategy Has Shown Life Thus Far (NASDAQ:KOD) 2022/11/14 18:17:47 Seeking Alpha
Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Read the outlook here.
Kodiak Sciences Inc. (KOD) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/11 12:24:00 US Post News
The share price of Kodiak Sciences Inc. (NASDAQ:KOD) rose to $7.12 per share on Thursday from $6.73. While Kodiak Sciences Inc. has overperformed by 5.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KOD fell by -93.63%, with highs and lows ranging from $116.78 to $4.90, […]